logo
  

Quest Diagnostics To Acquire Laboratory Services Business Of BBPL - Quick Facts

Quest Diagnostics Inc. (DGX), a provider of diagnostic information services, said Tuesday that it agreed to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories or BBPL, a provider of diagnostic and clinical laboratory services in the Midwest. Financial terms of the transaction were not disclosed.

BBPL's anatomic pathology division, Boyce and Bynum Pathology Professional Services, Inc. or BBPPS, and long-term care division are not part of the transaction, Quest said.

Quest noted that through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest Diagnostics' clients in Missouri and a preferred pathology provider in the greater Midwestern region.

The professional services agreement will go into effect at the time the acquisition is completed, which is expected in the first quarter of 2019.

According to Quest, the relationship between BBPL and the company will result in a broader menu of clinical laboratory and anatomic pathology services throughout the region. The relationship will also give patients access to an expanded network of service centers across the Midwest, for greater convenience.

"This relationship will extend our ability to provide the most innovative, cost-efficient services to patients and providers in the nation's heartland, deepening our presence in the region. It is consistent with our accelerate growth strategy, which includes delivering one to two percent in annual revenue through strategically aligned accretive acquisitions," said Steve Rusckowski, Chairman, President and CEO of Quest Diagnostics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast. Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand.
Follow RTT